Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Hickman Cancer Center at Flower Hospital
mi
from
Sylvania, OH
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Hickman Cancer Center at Flower Hospital
mi
from
Sylvania, OH
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Pharma Resource
mi
from
East Providence, RI
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Pharma Resource
mi
from
East Providence, RI
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Rhode Island Hospital
mi
from
Providence, RI
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
St. Vincent Hospital/Green Bay Oncology
mi
from
Green Bay, WI
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
St. Vincent Hospital/Green Bay Oncology
mi
from
Green Bay, WI
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
St. Mary's Hospital / Green Bay Oncology
mi
from
Green Bay, WI
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
St. Mary's Hospital / Green Bay Oncology
mi
from
Green Bay, WI
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Christiana Care Health Services, Inc
mi
from
Newark, DE
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Compass Research, LLC
mi
from
Orange City, FL
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Compass Research, LLC
mi
from
Orange City, FL
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Cancer Care Centers of Brevard
mi
from
Rockledge, FL
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Cancer Care Centers of Brevard
mi
from
Rockledge, FL
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Suburban Hematology-Oncology Associates
mi
from
Snellville, GA
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Suburban Hematology-Oncology Associates
mi
from
Snellville, GA
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Illinois Cancercare, Pc
mi
from
Peoria, IL
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Illinois Cancercare, Pc
mi
from
Peoria, IL
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
John Hopkins University
mi
from
Baltimore, MD
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
John Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Henry Ford Health System
mi
from
Detroit, MI
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
The Mayo Clinic
mi
from
Rochester, MN
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Regions Hospital
mi
from
Saint Louis Park, MN
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Regions Hospital
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Mercy Cancer Center
mi
from
Toledo, OH
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Mercy Cancer Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/4/2015
Miriam Hospital
mi
from
Providence, RI
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/4/2015
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease
Status: Enrolling
Updated:  9/10/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease
Status: Enrolling
Updated: 9/10/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
An Exploratory Study of Chemotherapy for Metastatic Colorectal Cancer Based Upon Thymidine Phosphorylase Expression, KRAS and BRAF Mutation Status, and ERCC1 Expression
Status: Enrolling
Updated:  9/10/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
An Exploratory Study of Chemotherapy for Metastatic Colorectal Cancer Based Upon Thymidine Phosphorylase Expression, KRAS and BRAF Mutation Status, and ERCC1 Expression
Status: Enrolling
Updated: 9/10/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
Status: Enrolling
Updated:  9/10/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
Status: Enrolling
Updated: 9/10/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cedar Rapids Oncology Associates
mi
from
Cedar Rapids, IA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cedar Rapids Oncology Associates
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Mercy Regional Cancer Center at Mercy Medical Center
mi
from
Cedar Rapids, IA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Mercy Regional Cancer Center at Mercy Medical Center
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
John Stoddard Cancer Center at Iowa Methodist Medical Center
mi
from
Des Moines, IA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
John Stoddard Cancer Center at Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
John Stoddard Cancer Center at Iowa Methodist Medical Center
mi
from
Des Moines, IA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
John Stoddard Cancer Center at Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
mi
from
Des Moines, IA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Medical Oncology and Hematology Associates at Mercy Cancer Center
mi
from
Des Moines, IA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Medical Oncology and Hematology Associates at Mercy Cancer Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Mercy Cancer Center at Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Mercy Cancer Center at Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Siouxland Hematology-Oncology Associates, LLP
mi
from
Sioux City, IA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Siouxland Hematology-Oncology Associates, LLP
mi
from
Sioux City, IA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
St. Luke's Regional Medical Center
mi
from
Sioux City, IA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
St. Luke's Regional Medical Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Associates in Womens Health, PA - North Review
mi
from
Wichita, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Associates in Womens Health, PA - North Review
mi
from
Wichita, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Via Christi Cancer Center at Via Christi Regional Medical Center
mi
from
Wichita, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Via Christi Cancer Center at Via Christi Regional Medical Center
mi
from
Wichita, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Click here to add this to my saved trials
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated:  9/18/2015
Hickman Cancer Center at Bixby Medical Center
mi
from
Adrian, MI
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Status: Enrolling
Updated: 9/18/2015
Hickman Cancer Center at Bixby Medical Center
mi
from
Adrian, MI
Click here to add this to my saved trials